Bridgeway Capital Management’s Yarrow Bioscience YARW Stock Holding History

Bridgeway Capital Management’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,539	Closed	-$25.8K	–	1290
2025 Q3	$25.8K	Hold	1,539	–	–	﹤0.01%	1186
2025 Q2	$127K	Buy	1,539 +500	+48%	+$32.5K	﹤0.01%	1035
2025 Q1	$82.1K	Buy	1,039 +300	+41%	+$36.9K	﹤0.01%	1071
2024 Q4	$124K	Buy	+739	New	+$96.7K	﹤0.01%	1085
2020 Q2	–	Sell	-29	Closed	-$283K	–	1406
2020 Q1	$283K	Sell	29 -9	-24%	-$141K	0.01%	948
2019 Q4	$629K	Buy	38 +1	+3%	+$16.7K	0.01%	885
2019 Q3	$596K	Hold	37	–	–	0.01%	877
2019 Q2	$789K	Hold	37	–	–	0.01%	815
2019 Q1	$1.03M	Buy	37 +2	+6%	+$48K	0.01%	754
2018 Q4	$515K	Hold	35	–	–	0.01%	991
2018 Q3	$1.23M	Buy	+35	New	+$1.08M	0.01%	799

Other funds holding YARW

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Deeter Investments Austin, Texas $468M AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

T3 Companies New York $93.7M AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

KCA

KVP Capital Advisors San Francisco, California $136M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Bridgeway Capital Management's YARW Position: Q4 2025 in Review

Bridgeway Capital Management sold out of Yarrow Bioscience (YARW) in Q4 2025, closing a stake of 1,539 shares — an estimated $25.8K sold.

Bridgeway Capital Management first reported a position in YARW in Q3 2018 and held it in 11 quarters. The position peaked at $1.23M in Q3 2018. 42 funds tracked by Wall St. Rank hold YARW as of Q4 2025.

Bridgeway Capital Management reported no remaining Yarrow Bioscience position as of Q4 2025 after selling out during the quarter.
Bridgeway Capital Management sold 1,539 Yarrow Bioscience shares in Q4 2025, an estimated $25.8K.
Bridgeway Capital Management first reported a position in Yarrow Bioscience in Q3 2018 and held it in 11 quarters.
Bridgeway Capital Management's Yarrow Bioscience position peaked at $1.23M in Q3 2018.
42 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q4 2025.

Based on Bridgeway Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.